Providence Therapeutics, University Health Network (UHN)와 mRNA 치료제 후보물질 발굴과 개발을 위한 파트너십 체결
June 02, 2023 11:41 ET
|
Providence Therapeutics
캐나다 앨버타주 캘거리, June 03, 2023 (GLOBE NEWSWIRE) -- 메신저 리보핵산(mRNA) 백신, 치료제 개발사인 Providence Therapeutics Holdings Inc.는 University Health Network (UHN)와 mRNA 신약 후보물질 발굴에 대한 파트너십을 체결했다고 발표했다. UHN은...
Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development
June 02, 2023 09:00 ET
|
Providence Therapeutics
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today...
Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer
February 01, 2023 08:00 ET
|
Providence Therapeutics
CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today...
Providence Therapeutics Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
December 15, 2022 08:00 ET
|
Providence Therapeutics
Novel rabies vaccine candidate developed with Providence’s mRNA platform further validates the technology Providence continues to expand its mRNA platform to target infectious diseases and oncology ...
Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress
November 28, 2022 08:00 ET
|
Providence Therapeutics
Presentation highlights data from PRO-CL-002 Phase 2 study of Providence’s mRNA COVID-19 vaccine candidate, PTX-COVID19-BPTX-COVID19-B was well tolerated with no safety signals; non-inferior to...
Providence Therapeutics Appoints Judyanna Yu as Chief Financial Officer
November 02, 2022 08:00 ET
|
Providence Therapeutics
CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics,...
Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults
October 19, 2022 08:00 ET
|
Providence Therapeutics
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase 3 trial of PTX-COVID19-B in...